study question: Is the age at menopause in a cohort of childhood cancer survivors earlier and what are the risk factors associated with earlier age at menopause? summary answer: Menopause occurred at a median age of 44 years in this cohort which is earlier than in the general population, but premature menopause was uncommon. Main risk factors for non-surgical menopause were exposure to and dose of alkylating agents, especially during adolescence, radiation dose to the ovaries and oophorectomy.
Introduction
Survival rates for children and adolescents with cancer have increased markedly over the past 30 years; currently, .70% of children and adolescents diagnosed with cancer can expect to be long-term survivors (Desandes et al., 2008) . However, with increased survival, survivors now face consequences of exposure to intensive therapies. The reproductive system is a vulnerable site for these effects and future fertility potential is a major concern for survivors. Ovarian failure during or shortly after completing cancer therapy is known to occur in a small number of females [6.3% in Childhood Cancer Survivor Study (CCSS)] diagnosed with childhood malignancy (Chemaitilly et al., 2006) . Ovarian exposure to high-dose radiation (.10 Gy), alkylating agents (especially procarbazine) given during adolescence and highdose alkylating agent regimens before stem cell transplantation (especially busulfan) have been shown to increase the rate of ovarian failure (Whitehead et al., 1983; Teinturier et al., 1998; Couto-Silva et al., 2001; De Bruin et al., 2008) .
Survivors who still menstruate after childhood or adolescent cancer therapy are known to be at increased risk for developing premature menopause, defined as cessation of menses before the age of 40 years (Byrne et al., 1992; Chiarelli et al., 1999; Sklar et al., 2006) . Premature menopause not only leads to infertility but is also associated with an increased incidence of osteoporosis and cardiovascular mortality (Shuster et al., 2010) . Data on premature menopause incidence and factors associated with its development after childhood cancer are limited, but the few that exist suggest that exposure to alkylating agents and radiation dose to the ovaries are major risk factors (Byrne et al., 1992; Chiarelli et al., 1999; Sklar et al., 2006) . Previous studies suffer from a number of limitations, including small sample size, lack of radiation dosimetry to ovaries or cumulative dose of drugs, failure to separate causes of premature menopause and the relatively young age of the survivors in these cohorts.
Thus, we evaluated age at menopause in a French cohort of survivors of childhood and adolescent cancer in which 32% have attained 40 years of age, determined the risk factors for an earlier menopause and assessed the incidence of premature menopause.
Patients and Methods

Euro2K cohort
The Euro2K cohort is an ongoing multicenter epidemiologic follow-up study of 5-year survivors of childhood solid histologically confirmed malignancy, who were diagnosed before the age of 18 years, between 1 January 1945 and 31 December 1985 in five French centers (De Vathaire et al., 1999) . The aim of this cohort is to study late adverse effects and mortality rate following treatment. A local ethical committee has approved all questionnaires and study documents.
Detailed medical information was taken from the medical record of each patient. Data collected included primary tumor type grouped according to a widely accepted classification system based principally on histology (Birch and Marsden, 1987) , all treatments for primary cancer, including cumulative doses of each chemotherapeutic agent expressed in milligrams per square metre, surgical procedures and quantitative data on radiation field and dose. A detailed description of the chemotherapy received by the cohort has been published elsewhere (De Vathaire et al., 1999) .
Menopause study
Of the 3402 French participants in the Euro2K study, 1522 were female. After the exclusion of the 69 patients treated with brachytherapy or with no available dosimetry, 1453 patients were included in the present analysis. Vital status of the Euro2k cohort patients was obtained by matching the first and last name, date and place of birth, as recorded in the hospital files, with the National Identification Registry. Three hundred and forty-four individuals were deceased.
Among the 1109 still-living female patients, 863 (78%) returned the first follow-up questionnaire. This questionnaire requested the information on age at menarche, current menstrual status, oral contraceptive and hormone use, endocrine disease, menopausal status and age at last menstrual period. Women with 12 months of amenorrhea and reporting menopause were defined as menopausal. The age at menopause was calculated with the date of final menstruation. The etiology of menopause, i.e. surgical (hysterectomy and/or bilateral oophorectomy), artificial secondary to medical therapy (use of hormonal therapy such as progesterone, gonadotrophin-releasing hormone analogs, hormonal treatment for secondary breast cancer), chemo or radiotherapy-induced during Figure 1 Flow chart of the cohort of women having survived 5 years to a solid cancer during childhood.
Age at menopause in survivors of childhood cancer treatment of a secondary cancer or natural was self-reported. Subjects who indicated that they had undergone induced menopause provided more information about its specific etiology, i.e. the precise type of surgical procedure performed and its etiology. In 149 cases, the quality of the provided data did not allow to precise menopausal status or its etiology and so we called 59 patients and examined 90 clinical reports to complete these data. Pubertal period was defined as the period beginning 2 years before first menses and ending at first menses.
Patients with hypopituitarism or acute ovarian failure could not be included in our study because they are not evaluable. Therefore, we excluded, respectively, 94 and 52 patients, based on never having spontaneous menses or ceased spontaneous menstruation within the first 5 years following the initial cancer diagnosis, or having reported information on hormonal treatments, including growth hormone treatment, or having received radiation dose .30 Gy to the pituitary gland.
Lastly, we excluded 15 women for unavailable data on menopausal status or age at last menstrual period. A total of 157 patients were excluded (Fig. 1) .
Chemotherapy
Drugs were analysed first by class according to their known mechanisms of action in the cell: vinca-alkaloids, anti-metabolites, alkylating agents, anthracyclines, cytotoxic antibiotics, epipodophylotoxins and other drugs. For each drug, the total dose per square meter of body surface area was calculated for each survivor. Table I summarizes the doses of each chemotherapeutic agent received. In the analyses, exposures to each drug were considered first as categorical variable (yes or no) and then as continuous variable (dose).
Radiation dosimetry
Hospital physicists obtained radiotherapy data from technical radiotherapy records for all included patients. For each of these patients, the absorbed doses to anatomical organs/sites were estimated according to the patients' gender, age and height at radiation, using Dos_Eg_Software (François et al., 1988a,b) . All information on data, reliability and validity of the methods used in this software to estimate the absorbed doses of radiotherapy can be found in our previous publications (François et al., 1988a,b; Diallo et al., 1996; Shamsaldin et al., 1998) . For 56 patients, technical records were either missing or incomplete and typical treatment was simulated.
Radiation dose to the estimated location of the ovaries, uterus, pelvis, abdomen, as well as to 180 other anatomical sites including pituitary gland were thus reconstructed. The minimal radiation dose to the ovaries was defined as the lowest dose between the right and left ovary, taking into account surgical removal of ovary if done.
Statistical Analysis
Descriptive analyses were done using the computer program SAS w V9. Univariate and multivariate analyses were performed using an adaptation of the Cox proportional hazard regression model (Cox, 1972) , using the AMFIT and PEANUTS modules of the EPICURE statistical software package (Preston et al., 1993) for fitting at each given age, directly the relative risk (RR) (rather than its log as in a classical Cox proportional hazard regression model) as a linear function of the dose (either radiation in gray or a drug in gram per square meter). We verified that both for radiation dose, cyclophosphamide and procarbazine doses in gram per square meter, the linear model was the best one and that adding a quadratic or an exponential term for departure from linear dose-response did not improve the fit of the model. Time to event was calculated from the birth to the age at menopause or date of completion of the questionnaire. The association between exposure to treatment modalities and the RR for menopause was analyzed stratifying by year of diagnosis-related groups (1965-1970, 1970-1975, 1975-1980 and 1980-1985) to take into account the changes in radiotherapy machines over time.
Kaplan -Meier curves of proportion of survivors still menstruating were drawn to illustrate the occurrence of non-surgical menopause by age, according to treatment exposures. Women with surgically induced menopause or amenorrhea due to treatment for secondary cancer or hormonal therapy (n ¼ 11) were censored at the time of these events in the analysis of non-surgical menopause. Ninety-five percent confidence intervals (95% CI) were estimated using maximum likelihood methods. All statistical tests were two-sided and a P-value of ,0.05 was considered as statistically significant.
Results
A total of 706 subjects were studied. The characteristics of analyzed, non-responding, excluded and deceased women are detailed in Table II. The groups differed by age at diagnosis, cancer diagnosis and treatment received. The main differences in cancer diagnosis between the analyzed and non-responding groups were the relative excess in retinoblastoma, brain tumors and other tumors in the non-responding group. The median age at cancer diagnosis of the analyzed population was 4 years (range: 0-17) and the median age at completion of the questionnaire was 36 years (range: 21-66); 77% of subjects had reached age 30 years, 32% age 40 and 7% were older than 50 years. The incidence of acute ovarian failure in this cohort is 6% (52/863). Ninety-seven women (13.7%) had become menopausal at a median age of 44 years (range: 18-55 years). In 35 (36%) of them, menopause had been surgically induced.
Age at menopause
The minimal radiation dose to the ovaries was associated with an excess risk of having a non-surgical menopause at a given age of 10% per gray received. The risk of menopause increased significantly with increasing dose of radiation to the ovaries: compared with exposure to ,0.01 Gy, RRs for non-surgical menopause were, respectively, 1.3 for doses between 0.01 and ,1 Gy, 2.3 for doses between 1 and ,10 Gy and 3.8 for 10 Gy or more (P for trend ¼ 0.004) (Table III) . Age or pubertal status at radiotherapy did not influence this risk. In a Cox multivariate regression model, only the following factors were found to significantly increase the risk of having a non-surgical menopause: chemotherapy and alkylating agents administration, radiation dose to the ovaries and unilateral oophorectomy (Table III) . Menopause occurred 4-year earlier in women who received alkylating agents compared with those who did not (median: 47 years, 95% CI: 45 -48, versus 51 years, 95% CI: 49-52). Compared with patients treated before the onset of pubertal period without alkylating agents or radiation to the ovaries, survivors treated after the onset of pubertal period with alkylating agents alone or even with a low-radiation dose to the ovaries had, respectively, a 9-and 29-fold higher rate of non-surgical menopause at a given age (Table IV) . Pubertal status at treatment was significantly associated with a higher risk of non-surgical menopause (P ¼ 0.0003 after treatment with alkylating agents alone and P , 0.0001 with alkylating agents and radiation dose to ovaries ≥1 Gy).
When controlling for pubertal status at the time of cancer treatment and treatment received, diagnosis (even Hodgkin's disease) did not play any role in the risk of being menopausal in our study.
When studying the role of each drug and dose exposure, only procarbazine, cyclophosphamide and melphalan were found to be associated with age at non-surgical menopause (Table III) . Treatment with procarbazine gave an excess risk of having a non-surgical menopause at a given age of 150% per gram received. Treatment with cyclophosphamide gave an excess risk of non-surgical menopause of 30% per gram received. No deviance from linearity was evidenced whatever the test for these last analyses.
Unilateral oophorectomy performed for initial cancer therapy (n ¼ 28) or other causes (n ¼ 12) was associated with a 6-fold higher risk of menopause, mainly surgical menopause (RR ¼ 6.3, 95% CI: 3.3 -12.2, P , 0.0001 for any type of menopause, RR ¼ 3.7, 95% CI: 1.111.2, P ¼ 0.03 for non-surgical menopause). Among these 40 women who underwent unilateral oophorectomy (median age: 37 years), 40% have reached menopause versus 11% of those who did not (median age: 35 years). We observed a 7-year earlier age at menopause in women who underwent unilateral oophorectomy (median: 42 years, 95% CI: 40-46 versus 49 years, 95% CI: 48 -50) (Fig. 2) . Figure 3 show the proportion of survivors still menstruating according to treatment exposure. The mean age at non-surgical menopause was, respectively, 50.8 + 1 years in women who were not exposed to alkylating agents nor radiation dose to the ovaries, 50.1 + 1.2 in those exposed only to radiation dose to the ovaries, 45.3 + 0.8 in those exposed only to alkylating agents and 45.9 + 1.2 in those exposed both to alkylating agents and radiation dose to the ovaries. Having received even a low dose of radiation to both ovaries was associated with a lower proportion of survivors not menopausal at 45 years in comparison with survivors exposed to no radiation to ovaries. Exposure to alkylating agents was associated with a 4-year earlier menopause.
Premature menopause
A total of 29 survivors had ceased menstruating before the age of 40 and were considered to have developed premature menopause. For 14 (48%) of them, menopause had been surgically induced. After censorship of eight women whose premature menopause was due to treatment for second cancer or hormonal therapy, the incidence of premature menopause was 6% (3.8-9.3%) and 2.1% (1 -4.7%) for non-surgical premature menopause among women who have attained 40 years of age. Only seven survivors developed non-surgical premature menopause. A Cox multivariate regression model controlling for age indicated the following risk factors for non-surgical premature menopause: age at diagnosis (RR ¼ 1.3, 95% CI: 1.04 -1.6, P ¼ 0.02), exposure to melphalan (RR ¼ 32, 95% CI: 2-530, P ¼ 0.02), cumulative dose of cyclophosphamide (RR ¼ 1.1, 95% CI: 1.02 -1.3, P ¼ 0.02) and radiation dose to the ovaries (RR ¼ 1.1, 95% CI: 1-1.2, P ¼ 0.003). Small numbers of women with non-surgical premature menopause did not allow for other analyses.
Among all non-menopausal women, 212 (35%) participants who self-reported as 'non-menopausal' were taking oral contraceptives continuously. Because menopausal status is not possible to assess in this condition, we reanalysed our data after excluding these women. The results of the multivariate Cox regression model after this exclusion remained unchanged.
Discussion
The median age of menopause is around 52 years in the general European population (Van Noord et al., 1997; Dratva et al., 2009) . Our study indicates that in a population of childhood solid cancer survivors comprising 50% of neuroblastoma and nephroblastoma, who did not experience acute ovarian failure, menopause occurs at an earlier median age (44 years). Nevertheless, the incidence of non-surgical premature menopause was only slightly elevated in this cohort compared with the general population (2.1% by age 40 versus 1%) (Luborsky, 2003) and was clearly lower than in the CCSS (8%) . Even if cancer types differ between our study and the CCSS one, treatments received in these two cohorts are similar: same percentage of survivors treated with surgery only (9 versus 10%), same rate of those treated with chemo and radiotherapy (48.5 versus 50%) but more survivors exposed to radiation dose to the ovaries .1 Gy in our cohort (28 versus 11%). So, the low premature menopause rate observed could be due to differences in chemotherapy received or radiotherapy methods or dosimetric evaluation. The risk factors that we identified (treatment with alkylating agents after pubertal onset and radiation dose to the ovaries) are in agreement with the findings from previous studies (Byrne et al., 1992; Chiarelli et al., 1999; Sklar et al., 2006) . Survivors treated after the onset of pubertal period with alkylating agents associated with even a low-dose of radiation to the ovaries had in our study a 29-fold higher rate of non-surgical menopause when compared with survivors treated before the onset of puberty without alkylating agents and radiation to the ovaries. This result is in accordance with other publication (Byrne et al., 1992; Chiarelli et al., 1999; Sklar et al., 2006) .
We found an association between age at non-surgical menopause and pubertal status at treatment. This is in agreement with the results from the Five-Center Study and those from Chiarelli et al., but differs from those reported from the CCSS cohort, in which the age at diagnosis was not found to be associated with an increased risk of premature menopause after adjusting for attained age (Byrne et al., 1992; Chiarelli et al., 1999; Sklar et al., 2006) . Our results should be viewed in light of our longer follow-up among survivors diagnosed at younger ages (median age at study in our cohort: 36 versus 29 years in the CCSS and 32% of survivors being .40 years in our cohort versus 8% in the CCSS) and existing data on age at first menses in this cohort. This provided us a better opportunity to evaluate the association between pubertal status at cancer treatment and the risk of non-surgical menopause. However, even if women treated with alkylating agents after the onset of puberty reached menopause at an earlier age than those treated before the onset of puberty, few of them experienced premature non-surgical menopause, i.e. before age 40. The younger age at diagnosis (median age at diagnosis 4 years old in our study versus 7 years old in the CCSS) could explain in part our lower premature menopause rate. 1950-1985) 1977 (1946-1985) 1977 (1951-1985) 1974 (1947-1985) 1977 (1946-1985) Age at diagnosis: median ( (93) 68 (233) 54 (784) Minimal radiation dose to the ovaries, % (n)
,0. This study incorporates detailed information on the cumulative doses of each chemotherapy drug received. This allowed us to clearly identify the role of procarbazine, cyclophosphamide and melphalan exposure on the age at menopause. Procarbazine, cyclophosphamide and melphalan are alkylating agents known to cause ovarian failure at high-cumulative dose or in association with other alkylating agents (Whitehead et al., 1983; Michel et al., 1997; Sarafoglou et al., 1997; Couto-Silva et al., 2001) .
Estimation of radiation dose to the ovaries confirmed that age at non-surgical menopause was correlated with radiation dose to the ovaries, even after low-dose exposure and regardless of age at exposure. This is consistent with a large literature indicating that ovaries are susceptible to damage from radiation therapy in a dose-dependent manner (Wallace et al., 2003) .
Unilateral oophorectomy was associated with a 7-year earlier age at menopause in our study. This fact has already been described in the general population, and is not surprising because removing one ovary diminishes the follicle pool by one-half, triggering earlier menopause (Hardy and Kuh, 1999) .
In contrast with the results from the CCSS, in our study, diagnosis of Hodgkin's disease did not confer an additional risk of being menopausal at a given age, nor of premature menopause when taking into account the treatments received and pubertal status at treatment but the small number of survivors from Hodgkin's disease in our study may be responsible for a lack in statistical power to show this effect .
We relied on self-report to determine the menopausal status and surgical causes of menopause, without confirmation from medical reports or hormonal assays for the majority of patients. Even if we called patients to specify menopausal status and surgical or medical treatment when self-reported data were not clear, some misclassification could have occurred. The fact that 35% of participants who selfreported as 'non-menopausal' were taking oral contraceptives likely resulted in an underestimation of the incidence of non-surgical menopause in this study. Moreover, because the estimated location of the ovaries is questionable in childhood patients, radiation dose estimation to the ovaries may not be completely accurate, but it is unlikely that our dosimetry has resulted in a systematic over-or underestimation of ovarian radiation dose. Finally, participants of this study have been treated from 1945 to 1985 and therapies have changed over time. Therefore, these results may not be strictly applicable to individuals treated with recent protocols, particularly with higher doses of chemotherapy in which we can expect a higher incidence of premature menopause. And lastly, we could not adjust the results to the genetic and environmental elements associated with menopause in the general population because of the lack of matched non-cancer survivor controls.
In conclusion, we have confirmed that survivors of childhood cancer treated with alkylating agents especially during adolescence are at risk of earlier menopause and that this risk is increased with radiation dose to the ovaries. We also identified the relationship between unilateral oophorectomy and age at menopause, mostly surgically induced menopause. Even if the incidence of premature menopause remains low in this cohort, one can expect a higher incidence with more recent protocols using high-dose of alkylating agents. C.T.T. and F.D.V. had full access to the data and take the responsibility of the integrity of the data and the accuracy of the data analysis. C.T.T. and F.D.V. contributed to study concept and design. C.E. 
